IL95377A - Pharmaceutical compositions for the treatment of peptic ulcer disease containing xanthine derivatives containing a tertiary hydroxylalkyl group and some novel compounds of this type - Google Patents

Pharmaceutical compositions for the treatment of peptic ulcer disease containing xanthine derivatives containing a tertiary hydroxylalkyl group and some novel compounds of this type

Info

Publication number
IL95377A
IL95377A IL9537790A IL9537790A IL95377A IL 95377 A IL95377 A IL 95377A IL 9537790 A IL9537790 A IL 9537790A IL 9537790 A IL9537790 A IL 9537790A IL 95377 A IL95377 A IL 95377A
Authority
IL
Israel
Prior art keywords
denotes
ethyl
compound
alkyl
hydroxy
Prior art date
Application number
IL9537790A
Other languages
English (en)
Other versions
IL95377A0 (en
Original Assignee
Hoechst Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan filed Critical Hoechst Japan
Publication of IL95377A0 publication Critical patent/IL95377A0/xx
Publication of IL95377A publication Critical patent/IL95377A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IL9537790A 1989-08-16 1990-08-14 Pharmaceutical compositions for the treatment of peptic ulcer disease containing xanthine derivatives containing a tertiary hydroxylalkyl group and some novel compounds of this type IL95377A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21018789 1989-08-16

Publications (2)

Publication Number Publication Date
IL95377A0 IL95377A0 (en) 1991-06-30
IL95377A true IL95377A (en) 1994-08-26

Family

ID=16585226

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9537790A IL95377A (en) 1989-08-16 1990-08-14 Pharmaceutical compositions for the treatment of peptic ulcer disease containing xanthine derivatives containing a tertiary hydroxylalkyl group and some novel compounds of this type

Country Status (18)

Country Link
US (1) US5109003A (de)
EP (1) EP0413278B1 (de)
JP (1) JP2977242B2 (de)
KR (1) KR910004620A (de)
AT (1) ATE144900T1 (de)
AU (1) AU624987B2 (de)
CA (1) CA2023310A1 (de)
DD (1) DD298051A5 (de)
DE (1) DE69029069T2 (de)
DK (1) DK0413278T3 (de)
ES (1) ES2094132T3 (de)
GR (1) GR3021569T3 (de)
HU (1) HU207518B (de)
IE (1) IE902954A1 (de)
IL (1) IL95377A (de)
NZ (1) NZ234896A (de)
PT (1) PT95007A (de)
ZA (1) ZA906446B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
US5354756A (en) * 1993-01-12 1994-10-11 Cell Therapeutics, Inc. Olefin-substituted long chain xanthine compounds
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
JPS63225317A (ja) * 1986-10-06 1988-09-20 Hoechst Japan Kk 抗消化性潰瘍剤
IL100536A (en) * 1986-12-31 1994-05-30 Hoechst Roussel Pharma Pharmaceutical preparations containing a history of xanthine Stopping an immune response and relieving adverse conditions resulting from intracellular intervention in an immune response
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤

Also Published As

Publication number Publication date
NZ234896A (en) 1993-10-26
HUT54688A (en) 1991-03-28
KR910004620A (ko) 1991-03-29
IE902954A1 (en) 1991-02-27
ES2094132T3 (es) 1997-01-16
ZA906446B (en) 1991-05-29
DD298051A5 (de) 1992-02-06
HU207518B (en) 1993-04-28
IL95377A0 (en) 1991-06-30
CA2023310A1 (en) 1991-02-17
JPH03163019A (ja) 1991-07-15
JP2977242B2 (ja) 1999-11-15
DE69029069D1 (de) 1996-12-12
EP0413278A3 (en) 1992-05-06
AU6101890A (en) 1991-02-21
DE69029069T2 (de) 1997-04-10
GR3021569T3 (en) 1997-02-28
ATE144900T1 (de) 1996-11-15
PT95007A (pt) 1991-04-18
EP0413278B1 (de) 1996-11-06
AU624987B2 (en) 1992-06-25
EP0413278A2 (de) 1991-02-20
DK0413278T3 (da) 1997-04-07
HU905000D0 (en) 1991-01-28
US5109003A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
JP3003333B2 (ja) アミノグリコシドにより誘発される腎毒性が実質的に減少されたアミノグリコシド組成物
RU2302420C2 (ru) Ингибиторы ксантин-фосфодиэстеразы v, способ их получения, фармацевтическая композиция, применение и способ лечения
IE840655L (en) 1,3-thiazolidine derivatives
WO1996004914A1 (en) Triazine derivative and medicine
EP0087810B1 (de) Antiphlogistische antipyretische analgesische pharmazeutische Zusammensetzungen mit Theophyllin-Derivaten als wirksame Bestandteile
EP0920868A1 (de) Eine kondensierte pyridazinverbindung enthaltendes heilmittel fuer erektionsstoerungen
CN111297866A (zh) 一种包含jak3/jak1/tbk1抑制剂和甲氨蝶呤的药物组合物及其用途
HU197842B (en) Process for producing pharmaceutical compositions comprising 2-alkoxy-n-(1-azabicyclo/2.2.2/oct-3-yl)-benzamide derivatives
US5082845A (en) Therapeutic xanthine derivatives for the treatment of peptic ulcer disease
IL95377A (en) Pharmaceutical compositions for the treatment of peptic ulcer disease containing xanthine derivatives containing a tertiary hydroxylalkyl group and some novel compounds of this type
US4845102A (en) Therapeutic agent for the treatment of peptic ulcer disease
US20200392099A1 (en) Agents and methods for treating dysproliferative diseases
WO2008061647A1 (en) Use of a compound as vegf inhibitor
AU716992B2 (en) Hydroquinone derivative and pharmaceutical use thereof
WO2006055573A2 (en) Methods of using pde v inhibitors for the treatment of congestive heart failure
JPH0559028A (ja) ベンゾチアゼピン誘導体、その塩類およびそれを含有する医薬組成物
JPS62289580A (ja) テオフイリンおよびテオブロミンのピペラジン誘導体
JPH04368327A (ja) キヌクリジン化合物またはその塩を含有する抗潰瘍剤
JPH1129478A (ja) ジヒドロキノリン誘導体を含有する医薬組成物

Legal Events

Date Code Title Description
RH Patent void